FUSEN PHARM (01652): Metformin and Linagliptin Tablets (I) Tentatively Win the Bid for the 11th Batch of National Drug Centralized Procurement Bidding in China.
Fosun Pharma (01652) issued an announcement on the 11th batch of national centralized procurement of drugs in China on October 27, 2025.
FUSEN PHARM (01652) announced that in the results of the 11th batch of National Drug Centralized Procurement Tender in China on October 27, 2025, one product of the group is intended to be selected: Metformin Glimepiride Tablets (I) ( Metformin Hydrochloride 500mg and Glimepiride 5mg ).
Related Articles
Beijing Chunlizhengda Medical Instruments (01858) released its performance for the first three quarters, with a net profit attributable to shareholders of 192 million yuan, a year-on-year increase of 213.21%.
KINGFAR PROPERTY (01354): Catalonia Property and Jingfa Supply Chain enter into a procurement framework agreement.
CHENMING PAPER(01812): Jiang Yanshan appointed as authorized representative
Beijing Chunlizhengda Medical Instruments (01858) released its performance for the first three quarters, with a net profit attributable to shareholders of 192 million yuan, a year-on-year increase of 213.21%.
KINGFAR PROPERTY (01354): Catalonia Property and Jingfa Supply Chain enter into a procurement framework agreement.
CHENMING PAPER(01812): Jiang Yanshan appointed as authorized representative
RECOMMEND
First in History: NVIDIA’s Market Capitalization Tops $5 Trillion
30/10/2025
Congressional Budget Office Estimates Government Shutdown Has Cost the U.S. Economy $18 Billion
30/10/2025
Wall Street on China’s Internet Sector: Distinct Investment Opportunities in AI and Gaming; Caution on E‑commerce
30/10/2025
